A smartphone sensor-based digital outcome assessment of multiple sclerosis.

Multiple sclerosis digital health technology mobile phone sensors smartphone wearable electronic devices

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
04 2022
Historique:
pubmed: 15 7 2021
medline: 5 4 2022
entrez: 14 7 2021
Statut: ppublish

Résumé

Sensor-based monitoring tools fill a critical gap in multiple sclerosis (MS) research and clinical care. The aim of this study is to assess performance characteristics of the Floodlight Proof-of-Concept (PoC) app. In a 24-week study (clinicaltrials.gov: NCT02952911), smartphone-based active tests and passive monitoring assessed cognition (electronic Symbol Digit Modalities Test), upper extremity function (Pinching Test, Draw a Shape Test), and gait and balance (Static Balance Test, U-Turn Test, Walk Test, Passive Monitoring). Intraclass correlation coefficients (ICCs) and age- or sex-adjusted Spearman's rank correlation determined test-retest reliability and correlations with clinical and magnetic resonance imaging (MRI) outcome measures, respectively. Seventy-six people with MS (PwMS) and 25 healthy controls were enrolled. In PwMS, ICCs were moderate-to-good (ICC(2,1) = 0.61-0.85) across tests. Correlations with domain-specific standard clinical disability measures were significant for all tests in the cognitive ( The Floodlight PoC app captures reliable and clinically relevant measures of functional impairment in MS, supporting its potential use in clinical research and practice.

Sections du résumé

BACKGROUND
Sensor-based monitoring tools fill a critical gap in multiple sclerosis (MS) research and clinical care.
OBJECTIVE
The aim of this study is to assess performance characteristics of the Floodlight Proof-of-Concept (PoC) app.
METHODS
In a 24-week study (clinicaltrials.gov: NCT02952911), smartphone-based active tests and passive monitoring assessed cognition (electronic Symbol Digit Modalities Test), upper extremity function (Pinching Test, Draw a Shape Test), and gait and balance (Static Balance Test, U-Turn Test, Walk Test, Passive Monitoring). Intraclass correlation coefficients (ICCs) and age- or sex-adjusted Spearman's rank correlation determined test-retest reliability and correlations with clinical and magnetic resonance imaging (MRI) outcome measures, respectively.
RESULTS
Seventy-six people with MS (PwMS) and 25 healthy controls were enrolled. In PwMS, ICCs were moderate-to-good (ICC(2,1) = 0.61-0.85) across tests. Correlations with domain-specific standard clinical disability measures were significant for all tests in the cognitive (
CONCLUSION
The Floodlight PoC app captures reliable and clinically relevant measures of functional impairment in MS, supporting its potential use in clinical research and practice.

Identifiants

pubmed: 34259588
doi: 10.1177/13524585211028561
pmc: PMC8961252
doi:

Banques de données

ClinicalTrials.gov
['NCT02952911']

Types de publication

Clinical Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

654-664

Références

IEEE J Biomed Health Inform. 2021 Mar;25(3):838-849
pubmed: 32750915
Front Neurol. 2017 Mar 29;8:116
pubmed: 28424654
NPJ Digit Med. 2021 Feb 24;4(1):36
pubmed: 33627777
NPJ Digit Med. 2020 Jul 23;3:97
pubmed: 32715091
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
NPJ Digit Med. 2019 Dec 11;2:123
pubmed: 31840094
Physiol Meas. 2020 Jun 19;41(5):054002
pubmed: 32259798
J Neurol. 2020 Oct;267(10):2897-2909
pubmed: 32468119
Ann Clin Transl Neurol. 2020 Mar;7(3):288-295
pubmed: 32101388
J Med Internet Res. 2019 Aug 30;21(8):e14863
pubmed: 31471961
J Neurol. 2021 Feb;268(2):590-601
pubmed: 32880724
J Neurol. 2017 Feb;264(2):316-326
pubmed: 27896433
Neurology. 2015 Feb 24;84(8):784-93
pubmed: 25632085
Brain. 1998 Jan;121 ( Pt 1):3-24
pubmed: 9549485
F1000Res. 2017 Oct 12;6:1828
pubmed: 29093810
Front Neurol. 2019 May 28;10:358
pubmed: 31191424
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
JMIR Mhealth Uhealth. 2020 Oct 5;8(10):e18160
pubmed: 33016886
Neurology. 2019 Nov 19;93(21):e1921-e1931
pubmed: 31641014
Front Immunol. 2015 Oct 19;6:520
pubmed: 26539193
Mov Disord. 2018 Aug;33(8):1287-1297
pubmed: 29701258
JAMA Neurol. 2020 Sep 1;77(9):1132-1140
pubmed: 32511687
Mult Scler. 2006 Dec;12(6):782-6
pubmed: 17263007
PLoS One. 2018 May 1;13(5):e0196463
pubmed: 29715279
Mult Scler. 2019 Nov;25(13):1809-1818
pubmed: 30381987
Sensors (Basel). 2020 Oct 19;20(20):
pubmed: 33086734
PLoS One. 2016 Mar 10;11(3):e0151195
pubmed: 26962853
Neurology. 2015 Nov 24;85(21):1904-8
pubmed: 26333795
Mult Scler. 2020 Apr;26(5):605-608
pubmed: 31965896

Auteurs

Xavier Montalban (X)

Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Jennifer Graves (J)

Department of Neurosciences, University of California San Diego, San Diego, CA, USA.

Luciana Midaglia (L)

Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain and Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.

Patricia Mulero (P)

Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Laura Julian (L)

Genentech, Inc., South San Francisco, CA, USA.

Michael Baker (M)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Jan Schadrack (J)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Christian Gossens (C)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Marco Ganzetti (M)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Alf Scotland (A)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Florian Lipsmeier (F)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Johan van Beek (J)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Corrado Bernasconi (C)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Shibeshih Belachew (S)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Michael Lindemann (M)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Stephen L Hauser (SL)

UCSF Weill Institute for Neurosciences and Department of Neurology, University of California San Francisco, San Francisco, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH